- Question from Mare74: I am at high risk for cardiac disease. I am taking Arimidex after lumpectomy and radiation and am interested in your opinion on the new results on trials of Evista.
- Answers - Generosa Grana, M.D., F.A.C.P While Evista (chemical name: raloxifene) is an interesting drug, its role is established only in the prevention setting, e.g., high-risk women using the drug to reduce their risk of breast cancer. There is very little data of Evista in metastatic breast cancer and none in either invasive disease or ductal carcinoma in situ. So for invasive breast cancer, the options remain tamoxifen or an aromatase inhibitor, such as Arimidex (chemical name: anastrozole), Femara (chemical name: letrozole), or Aromasin (chemical name: exemestane). There is no role in these patients for Evista.
The Ask-the-Expert Online Conference called Updates From the 2008 ASCO Annual Meeting featured Generosa Grana, M.D., F.A.C.P. and Carol Kaplan, M.D. answering your questions about the latest research advances on screening, treatment, side effects, and more.
Editor's Note: This conference took place in June 2008.
The materials presented in these conferences do not necessarily reflect the views of Breastcancer.org. A qualified healthcare professional should be consulted before using any therapeutic product or regimen discussed. All readers should verify all information and data before employing any therapies described here.
A production of LiveWorld, Inc.
Copyright 2010. All rights reserved.